News
Recent updates from Akiram Therapeutics.
Subscribe here to receive news and press releases to your email.
-
New JNM publication strengthens the scientific foundation for AKIR001
Akiram Therapeutics, a Swedish biotech company specializing in molecular radiotherapy, announces that new preclinical data on its lead candidate AKIR001 have been published in The Journal of Nuclear Medicine. The results demonstrate selective tumor uptake, clear antitumor effects, and favorable tolerability in preclinical pancreatic cancer models, further strengthening the scientific foundation for AKIR001. The article…
-
AKIR001 advances to cohort 3 in Phase I trial
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that cohort 2b in the ongoing Phase I clinical trial evaluating the drug candidate 177Lu-AKIR001 has been completed. Following the safety review, the study has advanced to cohort 3. The results continue to support a favorable safety profile, enabling further dose escalation and evaluation of…
-
Marika Nestor featured in SSF’s Om Vetenskap podcast
How can drugs be designed to target diseased cells with high precision? In a recent episode of Om Vetenskap, the podcast by the Swedish Foundation for Strategic Research (SSF), Akiram Therapeutics’ CEO and co-founder, Professor Marika Nestor, discusses the development of targeted radiopharmaceutical therapies and their potential to transform cancer treatment. The episode explores the…
-
AKIR001 study selected as overall featured article in The Journal of Nuclear Medicine
The preclinical study underpinning the clinical development of Akiram Therapeutics’ lead candidate AKIR001, published in The Journal of Nuclear Medicine (JNM), has been selected as best basic investigation and overall featured article for the February issue. An image from the article also appears on the cover. AKIR001 is developed by Akiram Therapeutics, a Swedish biotech…
-
Cohort 2a completed and cohort 2b cleared to start in Phase I trial of AKIR001
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. Cohort 2a investigated a higher activity dose than the run-in cohort. The results aligned with earlier findings, demonstrating continued favorable safety and encouraging tumor uptake. The trial is…
-
AKIR001 publication in The Journal of Nuclear Medicine supports ongoing clinical development
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that data on its CD44v6-targeted radiotherapeutic candidate AKIR001 have been published in The Journal of Nuclear Medicine, one of the leading journals in nuclear medicine. The publication summarizes key studies underpinning the ongoing first-in-human Phase 1 trial at Karolinska University Hospital. It reports high…
-
A pioneer in targeted radiotherapy – Marika Nestor featured in Onkologi i Sverige
What drives a cancer researcher to start a biotech company? In a newly published feature in Onkologi i Sverige, our CEO and co-founder, Professor Marika Nestor, shares insights from her journey through academia, innovation, and translational cancer research. The article traces her early steps into science, the growth of her all-female research group in Uppsala,…
-
Akiram Therapeutics research selected as Top Rated Oral Presentations at EANM 2025
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October 4–8. Two have been selected as Top Rated Oral Presentations, highlighting continued development of the CD44v6-targeting antibody used in the company’s clinical-stage radiopharmaceutical—currently being investigated in a Phase I clinical trial….
-
Clinical Phase I clinical trial with AKIR001 progresses to next step following completion of first cohort
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of the first cohort in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. No safety signals have been observed, and the trial is now proceeding to the next stage as planned. The trial is being conducted at Karolinska University Hospital,…
-
First patient enrolled in Phase 1 clinical trial of Akiram’s cancer drug candidate AKIR001
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts to…
-
Akiram Therapeutics initiates Eurostars-funded collaboration to develop next-generation targeted alpha-therapeutics
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit Technologies. The aim of the project is to develop a new generation of targeted alpha-therapeutics by expanding Akiram’s proprietary CD44v6-targeting antibody platform using advanced pre-targeting strategies and radiolabeling chemistry. The…
-
Leading the future of radioimmunotherapy for cancer treatment
Our CEO, Professor Marika Nestor discusses advancing cancer treatment through radioimmunotherapy in a new interview ahead of her presentation at Antibody Engineering & Therapeutics. The interview highlights Akiram’s recent milestone: the approval of a Phase 1 clinical trial for 177Lu-AKIR001, a novel radiolabeled antibody targeting cancers with high CD44v6 expression, including head and neck squamous…
-
Akiram Therapeutics’ drug candidate AKIR001 cleared to start Phase 1 clinical trial
Akiram Therapeutics, a Swedish biotech company specializing in molecular radiation therapy, announces that the Swedish Medical Products Agency has approved the initiation of a Phase 1 clinical trial for its drug candidate 177Lu-AKIR001. This marks a key milestone in the company’s development of a pioneering cancer treatment aimed at offering new hope for patients with…
-
New research advances on AKIR001 to be presented at EANM Congress 2024
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will participate in the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from October 19-23. At this year’s congress, research findings on Akiram’s drug candidate AKIR001, resulting from several successful academic collaborations, will be presented. Akiram Therapeutics has developed 177Lu-AKIR001, a new type…
-
Akiram Therapeutics announces agreement with leading university hospital on 177Lu-AKIR001 manufacturing for cancer therapy
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has entered into an agreement with a leading Swedish university hospital for the manufacturing of 177Lu-AKIR001, a radiopharmaceutical designed for treating patients with solid tumors. This agreement marks an important step towards the Phase I first-in-human study, which is planned to start in 2024. Akiram…
-
Akiram Therapeutics strengthens board with drug development expertise
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company’s position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024….
-
Akiram Therapeutics’ pioneering cancer research backed by SEK 6 million from the Erling-Persson Foundation
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder, Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of…
-
Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress
Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024….
-
DDD exit financed with 68 MSEK to develop novel cancer therapy
In June 2022, Marika Nestor’s project aiming to develop a novel cancer therapy left the DDD Platform at SciLifeLab. Six months later, the resulting spin-out company Akiram Therapeutics raised 68 MSEK and is heading for clinical trials in 2024. Read the full SciLifeLab news item here.
-
Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers
The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the…
-
She is creating brilliant chances for cancer patients
Radiopharmaceuticals that fight cancer are on the rise and Marika Nestor is doing everything she can to contribute to their development. An antibody from her lab offers hope for a future treatment for those affected by anaplastic thyroid cancer, a currently incurable form of cancer. Read the full news item from Uppsala University here (in…
-
Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer
A new antibody might be the first effective treatment for Anaplastic thyroid cancer (ATC), a very aggressive cancer type with a median survival of only 4-5 month even with available treatments. The radiolabeled antibody is the result of a four-year long successful collaboration between SciLifeLab researcher Marika Nestor (Uppsala University) and the SciLifeLab Drug Discovery…
